Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BBIO – BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.
BBIO
$43.55
Name : BridgeBio Pharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,263,620,608.00
EPSttm : -3.56
finviz dynamic chart for BBIO
BridgeBio Pharma, Inc.
$43.52
2.99%
$1.34

Float Short %

13.14

Margin Of Safety %

Put/Call OI Ratio

0.5

EPS Next Q Diff

0.28

EPS Last/This Y

0.54

EPS This/Next Y

0.47

Price

44.85

Target Price

60.56

Analyst Recom

1.35

Performance Q

23.24

Relative Volume

2.84

Beta

1.15

Ticker: BBIO




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02BBIO35.460.402.1972505
2025-06-03BBIO37.520.400.8572570
2025-06-04BBIO38.030.430.7274610
2025-06-05BBIO38.330.430.0175511
2025-06-06BBIO38.60.420.4076929
2025-06-09BBIO39.010.430.4178314
2025-06-10BBIO40.080.440.0878910
2025-06-11BBIO39.040.450.3377993
2025-06-12BBIO39.640.450.2178872
2025-06-13BBIO39.760.450.0278792
2025-06-16BBIO41.150.440.2479318
2025-06-17BBIO40.050.450.6979014
2025-06-18BBIO39.990.460.1179604
2025-06-20BBIO41.740.460.0879593
2025-06-23BBIO42.170.490.2972757
2025-06-24BBIO44.460.490.2173410
2025-06-25BBIO44.40.490.4074165
2025-06-26BBIO45.10.500.6374808
2025-06-27BBIO44.860.501.0575604
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02BBIO35.4868.5115.7-2.62
2025-06-03BBIO37.5268.5107.6-2.62
2025-06-04BBIO38.0268.5123.7-2.62
2025-06-05BBIO38.3476.7125.4-2.34
2025-06-06BBIO38.6076.7126.1-2.34
2025-06-09BBIO39.0376.7124.6-2.34
2025-06-10BBIO40.0876.7118.7-2.34
2025-06-11BBIO39.0461.0138.1-2.34
2025-06-12BBIO39.6561.0122.9-2.34
2025-06-13BBIO39.7561.0127.6-2.34
2025-06-16BBIO41.1561.0115.9-2.34
2025-06-17BBIO40.0561.0138.3-2.34
2025-06-18BBIO40.0061.0129.2-2.34
2025-06-20BBIO41.7361.0112.7-2.34
2025-06-23BBIO42.1761.0124.6-2.34
2025-06-24BBIO44.4461.0108.7-2.34
2025-06-25BBIO44.3761.0129.2-2.34
2025-06-26BBIO45.1161.0122.3-2.34
2025-06-27BBIO44.8561.0130.7-2.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02BBIO-35.814.7613.93
2025-06-03BBIO-35.814.7613.93
2025-06-04BBIO-35.814.7613.93
2025-06-05BBIO-35.814.7613.93
2025-06-06BBIO-35.814.7613.93
2025-06-09BBIO-35.814.7813.93
2025-06-10BBIO-35.814.7813.93
2025-06-11BBIO-35.814.7813.68
2025-06-12BBIO-35.814.7813.68
2025-06-13BBIO-35.814.7813.68
2025-06-16BBIO-35.814.8013.68
2025-06-18BBIO-35.814.8013.68
2025-06-20BBIO-35.814.8013.68
2025-06-23BBIO-35.814.9013.68
2025-06-24BBIO-35.814.9013.68
2025-06-25BBIO-35.814.9013.68
2025-06-26BBIO-35.814.9013.14
2025-06-27BBIO-35.954.9013.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.88

Avg. EPS Est. Current Quarter

-0.39

Avg. EPS Est. Next Quarter

-0.6

Insider Transactions

-35.95

Institutional Transactions

4.9

Beta

1.15

Average Sales Estimate Current Quarter

101

Average Sales Estimate Next Quarter

93

Fair Value

Quality Score

25

Growth Score

45

Sentiment Score

86

Actual DrawDown %

39

Max Drawdown 5-Year %

-92.8

Target Price

60.56

P/E

Forward P/E

PEG

P/S

66.85

P/B

P/Free Cash Flow

EPS

-3.53

Average EPS Est. Cur. Y​

-2.34

EPS Next Y. (Est.)

-1.87

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-524.25

Relative Volume

2.84

Return on Equity vs Sector %

16.6

Return on Equity vs Industry %

34.5

EPS 1 7Days Diff

EPS 1 30Days Diff

0.28

EBIT Estimation

130.7
BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 725
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
stock quote shares BBIO – BridgeBio Pharma, Inc. Stock Price stock today
news today BBIO – BridgeBio Pharma, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BBIO – BridgeBio Pharma, Inc. yahoo finance google finance
stock history BBIO – BridgeBio Pharma, Inc. invest stock market
stock prices BBIO premarket after hours
ticker BBIO fair value insiders trading